ALUR Stock Forecast 2025-2026
Distance to ALUR Price Targets
ALUR Price Momentum
10 Quality Stocks Worth Considering Now
Researching Allurion (ALUR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ALUR and similar high-potential opportunities.
Latest ALUR Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, ALUR has a bullish consensus with a median price target of $17.00 (ranging from $6.00 to $62.50). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $3.20, the median forecast implies a 431.3% upside. This outlook is supported by 3 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALUR Analyst Ratings
ALUR Price Target Range
Latest ALUR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALUR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | Roth MKM | Jason Wittes | Buy | Reiterates | $16.00 |
| Mar 21, 2025 | Chardan Capital | Keay Nakae | Neutral | Maintains | $2.50 |
| Nov 14, 2024 | Chardan Capital | Keay Nakae | Neutral | Downgrade | $0.00 |
| Oct 2, 2024 | TD Cowen | Joshua Jennings | Buy | Initiates | $2.00 |
| Sep 6, 2024 | Roth MKM | Jason Wittes | Buy | Initiates | $2.00 |
| Aug 22, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $2.50 |
| May 15, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $5.00 |
| Apr 4, 2024 | Chardan Capital | Keay Nakae | Buy | Initiates | $5.00 |
| Feb 9, 2024 | Jefferies | Matthew Taylor | Buy | Initiates | $5.00 |
Allurion Technologies Inc. (ALUR) Competitors
The following stocks are similar to Allurion based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Allurion Technologies Inc. (ALUR) Financial Data
Allurion Technologies Inc. has a market capitalization of $18.61M with a P/E ratio of 32.9x. The company generates $34.75M in trailing twelve-month revenue with a -71.2% profit margin.
Revenue growth is -70.5% quarter-over-quarter, while maintaining an operating margin of -162.9% and return on equity of +116.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Allurion Technologies Inc. (ALUR) Business Model
About Allurion Technologies Inc.
Develops non-invasive weight loss medical devices.
Allurion Technologies generates revenue primarily through the sale of its innovative medical device, the Elipse Balloon, which is aimed at promoting weight loss without surgical intervention. The company targets hospitals, clinics, and wellness centers, leveraging the growing demand for non-invasive weight management solutions in a global market.
With the increasing prevalence of obesity, Allurion's products address a significant health issue while potentially reducing healthcare costs. The company is also integrating digital tools to enhance patient support and monitoring, positioning itself at the convergence of health, technology, and consumer healthcare.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
501
CEO
Dr. Shantanu K. Gaur M.D.
Country
United States
IPO Year
2023
Website
www.allurion.comAllurion Technologies Inc. (ALUR) Latest News & Analysis
Allurion Technologies Inc. (NYSE: ALUR) will hold its Q4 2024 earnings conference call on March 26, 2025, at 8:30 AM ET, featuring company executives and analysts from various firms.
The earnings call provides insights on Allurion's performance and future outlook, influencing stock valuation and investor sentiment. Key analysts will be present, offering additional market perspectives.
Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
1 day agoAllurion Technologies (NYSE: ALUR) reported Q4 and full-year 2024 financial results, highlighting initial data on its program combined with low-dose GLP-1s and plans for further research.
Allurion Technologies' financial results and innovative combination therapy data could signal growth potential, impacting stock performance and investor sentiment in the obesity treatment sector.
Allurion Technologies, Inc. reported a quarterly loss of $7 per share, missing the Zacks Consensus Estimate of a $5 loss, compared to a loss of $15.75 per share a year prior.
Allurion's larger-than-expected quarterly loss raises concerns about its financial health and operational performance, potentially affecting stock valuation and investor confidence.
Allurion Technologies (NYSE: ALUR) reported initial results on combining its Allurion Program with low-dose GLP-1 therapy, involving 52 patients using semaglutide for muscle mass optimization.
Positive results from Allurion's therapy combination may enhance its product efficacy, potentially increasing demand and driving stock value. Market interest in obesity treatments could boost investor confidence.
Allurion Technologies, Inc. (NYSE: ALUR) will report Q4 2024 financial results on March 26, 2025, and host a conference call at 8:30 AM ET for updates.
Allurion's upcoming financial results and conference call could influence stock performance, providing insights into its growth and business strategy, impacting investor sentiment and decisions.
Allurion Technologies (NYSE: ALUR) announced receipt of two Issue Notifications from the USPTO for patents related to their balloon-filling catheter system, expected to be issued in March 2025.
Patent approvals can enhance Allurion's competitive edge and market position, potentially leading to increased revenue and investor confidence in future growth.
Frequently Asked Questions About ALUR Stock
What is Allurion Technologies Inc.'s (ALUR) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Allurion Technologies Inc. (ALUR) has a median price target of $17.00. The highest price target is $62.50 and the lowest is $6.00.
Is ALUR stock a good investment in 2025?
According to current analyst ratings, ALUR has 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.20. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALUR stock?
Wall Street analysts predict ALUR stock could reach $17.00 in the next 12 months. This represents a 431.3% increase from the current price of $3.20. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Allurion Technologies Inc.'s business model?
Allurion Technologies generates revenue primarily through the sale of its innovative medical device, the Elipse Balloon, which is aimed at promoting weight loss without surgical intervention. The company targets hospitals, clinics, and wellness centers, leveraging the growing demand for non-invasive weight management solutions in a global market.
What is the highest forecasted price for ALUR Allurion Technologies Inc.?
The highest price target for ALUR is $62.50 from at , which represents a 1,853.1% increase from the current price of $3.20.
What is the lowest forecasted price for ALUR Allurion Technologies Inc.?
The lowest price target for ALUR is $6.00 from at , which represents a 87.5% increase from the current price of $3.20.
What is the overall ALUR consensus from analysts for Allurion Technologies Inc.?
The overall analyst consensus for ALUR is bullish. Out of 4 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $17.00.
How accurate are ALUR stock price projections?
Stock price projections, including those for Allurion Technologies Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
